SK288100B6 - Human IL-2 mutein, pharmaceutical composition containing thereof and use, vector and prokaryotic host cell - Google Patents
Human IL-2 mutein, pharmaceutical composition containing thereof and use, vector and prokaryotic host cell Download PDFInfo
- Publication number
- SK288100B6 SK288100B6 SK1724-2000A SK17242000A SK288100B6 SK 288100 B6 SK288100 B6 SK 288100B6 SK 17242000 A SK17242000 A SK 17242000A SK 288100 B6 SK288100 B6 SK 288100B6
- Authority
- SK
- Slovakia
- Prior art keywords
- cells
- cell
- mutant
- human
- proleukin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8008098A | 1998-05-15 | 1998-05-15 | |
PCT/US1999/010643 WO1999060128A1 (en) | 1998-05-15 | 1999-05-13 | Il-2 selective agonists and antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
SK17242000A3 SK17242000A3 (sk) | 2001-07-10 |
SK288100B6 true SK288100B6 (sk) | 2013-07-02 |
Family
ID=22155135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1724-2000A SK288100B6 (sk) | 1998-05-15 | 1999-05-13 | Human IL-2 mutein, pharmaceutical composition containing thereof and use, vector and prokaryotic host cell |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP1076704B1 (de) |
JP (1) | JP4276783B2 (de) |
KR (1) | KR100607609B1 (de) |
CN (2) | CN101319247B (de) |
AR (1) | AR020322A1 (de) |
AT (1) | ATE351907T1 (de) |
AU (1) | AU759697B2 (de) |
BG (1) | BG65139B1 (de) |
BR (1) | BRPI9910504B1 (de) |
CA (1) | CA2327349C (de) |
CO (1) | CO5070701A1 (de) |
CU (2) | CU23273B7 (de) |
CY (1) | CY1107533T1 (de) |
CZ (1) | CZ302071B6 (de) |
DE (1) | DE69934881T2 (de) |
DK (1) | DK1076704T3 (de) |
DZ (1) | DZ2788A1 (de) |
ES (1) | ES2281175T3 (de) |
HK (1) | HK1039963B (de) |
HN (1) | HN1999000075A (de) |
HU (1) | HU226142B1 (de) |
IL (2) | IL139136A0 (de) |
MY (1) | MY130274A (de) |
NO (1) | NO329235B1 (de) |
NZ (1) | NZ508098A (de) |
PA (1) | PA8472601A1 (de) |
PE (1) | PE20000475A1 (de) |
PL (1) | PL201675B1 (de) |
PT (1) | PT1076704E (de) |
RO (1) | RO122150B1 (de) |
RU (1) | RU2235729C2 (de) |
SI (1) | SI20643B (de) |
SK (1) | SK288100B6 (de) |
SV (1) | SV1999000061A (de) |
TN (1) | TNSN99090A1 (de) |
TR (1) | TR200003354T2 (de) |
TW (1) | TWI223663B (de) |
UA (1) | UA73719C2 (de) |
WO (1) | WO1999060128A1 (de) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566500B1 (en) | 1999-03-30 | 2003-05-20 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
EP1935431A3 (de) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2 |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
US7723102B2 (en) * | 2000-09-28 | 2010-05-25 | Bayer Corporation | Enhanced transfection system |
MY139948A (en) * | 2000-09-28 | 2009-11-30 | Bayer Corp | Enhanced transfection system |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
CN100390282C (zh) | 2001-12-04 | 2008-05-28 | 默克专利有限公司 | 具有调节的选择性的il-2融合蛋白 |
US7569215B2 (en) * | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
DE602004031681D1 (de) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
JP4765039B2 (ja) | 2003-11-04 | 2011-09-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Cd40抗原を発現する癌に対する治療方法。 |
WO2005085282A1 (en) * | 2004-02-27 | 2005-09-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
BRPI0508470A (pt) * | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
CN101244261B (zh) * | 2008-03-10 | 2010-09-15 | 山东大学 | 一种含未复性重组蛋白的生物制剂及其制备方法与应用 |
DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
JP5766124B2 (ja) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
PT2637694T (pt) | 2010-11-12 | 2021-05-05 | Nektar Therapeutics | Conjugados de uma fração de il-2 e um polímero |
CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
EP3211001B1 (de) | 2010-12-22 | 2020-10-07 | The Board of Trustees of the Leland Stanford Junior University | Superagonisten und antagonisten von interleukin-2 |
BR112013018932B1 (pt) | 2011-02-10 | 2020-11-17 | Roche Glycart Ag | polipeptídeo de interleucina-2 (il-2) mutante, imunoconjugado, polinucleotídeo isolado, célula hospedeira de microrganismos, método de produção de um polipeptídeo de il-2 mutante, composição farmacêutica e usos do polipeptídeo de il-2 mutante ou do imunoconjugado |
WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
JP2016533167A (ja) | 2013-09-24 | 2016-10-27 | メディシナ セラピューティクス ピーティーイー リミテッド | インターロイキン−2融合タンパク質及びその使用 |
EP3102595B1 (de) | 2014-02-06 | 2018-11-07 | F.Hoffmann-La Roche Ag | Interleukin-2-fusionsproteine und verwendungen davon |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CN106659757B (zh) | 2014-04-24 | 2022-01-28 | 利兰斯坦福初级大学董事会 | 白介素2的超级激动剂、部分激动剂和拮抗剂 |
KR20170035910A (ko) * | 2014-08-11 | 2017-03-31 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체 |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
JP7178906B2 (ja) * | 2016-05-19 | 2022-11-28 | ザ ジェネラル ホスピタル コーポレイション | ナチュラルキラー細胞および制御性T細胞の活性を強化するためのプラットフォームである、その受容体IL-2Rβに繋ぎ止められたインターロイキン-2 |
TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
CA3028829A1 (en) * | 2016-06-22 | 2017-12-28 | David Klatzmann | Genetically modified t lymphocytes |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018089420A1 (en) | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
RU2769871C2 (ru) * | 2016-12-13 | 2022-04-07 | Делиниа, Инк. | Поливалентные модуляторы регуляторных t-клеток |
JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
WO2018217989A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
WO2018215938A1 (en) * | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
EP3641814A4 (de) | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | Verwendungen und verfahren für il-2-superagonisten, agonisten und fusionen davon |
AR112969A1 (es) * | 2017-08-03 | 2020-01-15 | Synthorx Inc | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas |
EP3713592A4 (de) * | 2017-11-21 | 2022-01-12 | The Board of Trustees of the Leland Stanford Junior University | Partielle agonisten von interleukin-2 |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
US11534479B2 (en) | 2018-02-16 | 2022-12-27 | Iltoo Pharma | Use of interleukin 2 for treating Sjögren's syndrome |
MX2020009857A (es) | 2018-03-28 | 2021-01-08 | Ascendis Pharma Oncology Div A/S | Conjugados de interleucina-2 (il-2). |
US11359000B2 (en) | 2018-03-28 | 2022-06-14 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
CN112771072A (zh) * | 2018-07-24 | 2021-05-07 | 生物技术Rna制药有限公司 | Il2激动剂 |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
US11492384B2 (en) * | 2018-09-17 | 2022-11-08 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
JP2022513265A (ja) | 2018-12-21 | 2022-02-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ヒトインターロイキン2の変異体またはその誘導体 |
KR20220035333A (ko) | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
KR20220044577A (ko) * | 2019-08-13 | 2022-04-08 | 암젠 인크 | T-조절 세포의 확장을 위한 인터류킨-2 돌연변이단백질 |
CA3159468A1 (en) | 2019-12-12 | 2021-06-17 | David Klatzmann | Interleukin 2 chimeric constructs |
WO2021127262A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
EP4087865A2 (de) | 2020-01-10 | 2022-11-16 | Bright Peak Therapeutics AG | Modifizierte il-2-polypeptide und verwendungen davon |
KR20240046306A (ko) | 2020-01-14 | 2024-04-08 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
WO2021185361A1 (zh) | 2020-03-19 | 2021-09-23 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
AU2021202825B2 (en) | 2020-03-31 | 2022-06-30 | Hanmi Pharm. Co., Ltd. | Novel immunostimulating IL-2 analogs |
AU2021286177A1 (en) | 2020-06-03 | 2022-12-01 | Ascendis Pharma Oncology Division A/S | IL-2 sequences and uses thereof |
IL302114A (en) | 2020-10-29 | 2023-06-01 | Bristol Myers Squibb Co | Fusion proteins for the treatment of diseases |
CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
CN113308477A (zh) * | 2021-04-08 | 2021-08-27 | 华南农业大学 | 一种鸭il-2基因真核表达重组质粒及其制备方法 |
IL311643A (en) | 2021-09-22 | 2024-05-01 | Fortvita Biologics Singapore Pte Ltd | Interleukin-2 mutant and fusion protein |
WO2023057588A1 (en) | 2021-10-06 | 2023-04-13 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
WO2023245097A2 (en) * | 2022-06-16 | 2023-12-21 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
FR3140287A1 (fr) | 2022-10-03 | 2024-04-05 | Arkema France | Procede de granulation de composes azoiques et granules obtenus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
-
1999
- 1999-05-12 DZ DZ990088A patent/DZ2788A1/xx active
- 1999-05-13 EP EP99924232A patent/EP1076704B1/de not_active Expired - Lifetime
- 1999-05-13 AU AU40784/99A patent/AU759697B2/en not_active Expired
- 1999-05-13 IL IL13913699A patent/IL139136A0/xx unknown
- 1999-05-13 PT PT99924232T patent/PT1076704E/pt unknown
- 1999-05-13 CN CN2007101609093A patent/CN101319247B/zh not_active Expired - Lifetime
- 1999-05-13 TN TNTNSN99090A patent/TNSN99090A1/fr unknown
- 1999-05-13 PE PE1999000399A patent/PE20000475A1/es not_active Application Discontinuation
- 1999-05-13 PL PL344407A patent/PL201675B1/pl unknown
- 1999-05-13 RO ROA200001123A patent/RO122150B1/ro unknown
- 1999-05-13 PA PA19998472601A patent/PA8472601A1/es unknown
- 1999-05-13 ES ES99924232T patent/ES2281175T3/es not_active Expired - Lifetime
- 1999-05-13 DE DE69934881T patent/DE69934881T2/de not_active Expired - Lifetime
- 1999-05-13 KR KR1020007012747A patent/KR100607609B1/ko not_active IP Right Cessation
- 1999-05-13 AT AT99924232T patent/ATE351907T1/de active
- 1999-05-13 CN CNB998086509A patent/CN100366742C/zh not_active Expired - Lifetime
- 1999-05-13 AR ARP990102269A patent/AR020322A1/es active IP Right Grant
- 1999-05-13 WO PCT/US1999/010643 patent/WO1999060128A1/en active IP Right Grant
- 1999-05-13 TR TR2000/03354T patent/TR200003354T2/xx unknown
- 1999-05-13 JP JP2000549735A patent/JP4276783B2/ja not_active Expired - Lifetime
- 1999-05-13 CA CA2327349A patent/CA2327349C/en not_active Expired - Lifetime
- 1999-05-13 DK DK99924232T patent/DK1076704T3/da active
- 1999-05-13 SI SI9920034A patent/SI20643B/sl active Search and Examination
- 1999-05-13 NZ NZ508098A patent/NZ508098A/en not_active IP Right Cessation
- 1999-05-13 RU RU2000131593/04A patent/RU2235729C2/ru active
- 1999-05-13 HU HU0101948A patent/HU226142B1/hu unknown
- 1999-05-13 SK SK1724-2000A patent/SK288100B6/sk not_active IP Right Cessation
- 1999-05-13 UA UA2000127206A patent/UA73719C2/uk unknown
- 1999-05-13 BR BRPI9910504A patent/BRPI9910504B1/pt not_active IP Right Cessation
- 1999-05-13 CZ CZ20004213A patent/CZ302071B6/cs not_active IP Right Cessation
- 1999-05-14 TW TW088107812A patent/TWI223663B/zh not_active IP Right Cessation
- 1999-05-14 SV SV1999000061A patent/SV1999000061A/es active IP Right Grant
- 1999-05-14 MY MYPI99001912A patent/MY130274A/en unknown
- 1999-05-14 HN HN1999000075A patent/HN1999000075A/es unknown
- 1999-05-14 CO CO99030158A patent/CO5070701A1/es unknown
-
2000
- 2000-10-18 IL IL139136A patent/IL139136A/en not_active IP Right Cessation
- 2000-11-08 BG BG104929A patent/BG65139B1/bg unknown
- 2000-11-14 NO NO20005762A patent/NO329235B1/no not_active IP Right Cessation
- 2000-11-15 CU CU20000257A patent/CU23273B7/es not_active IP Right Cessation
-
2002
- 2002-02-21 HK HK02101283.2A patent/HK1039963B/zh not_active IP Right Cessation
- 2002-06-19 CU CU20020125A patent/CU23272A1/es not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100330T patent/CY1107533T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK288100B6 (sk) | Human IL-2 mutein, pharmaceutical composition containing thereof and use, vector and prokaryotic host cell | |
US7105653B2 (en) | IL-2 selective agonists and antagonists | |
US5985262A (en) | Method of treatment with epithelium derived T-cell factor | |
US7186805B2 (en) | IL-21 antagonists | |
RU2369616C2 (ru) | Слитые белки il-7 | |
US8153114B2 (en) | Hyperglycosylated mammalian IL-7 IgG conjugate composition | |
JP4024366B2 (ja) | ポリペプチド | |
AU680909B2 (en) | Interleukin-15 | |
MXPA00010943A (en) | Il-2 selective agonists and antagonists | |
JP3689111B2 (ja) | インターロイキン15 | |
JP2007143555A (ja) | ポリペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Patent expired |
Expiry date: 20190513 |